Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iBio has announced the production of functional monoclonal antibody copy of Palivizumab leveraging the company's proprietary iBioLaunch technology.
Subscribe to our email newsletter
Palivizumab is a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells, thereby reducing RSV associated hospitalizations.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.
iBioLaunch-produced palivizumab has been shown to bind inactivated RSV, indicating that it recognizes F antigen presented on the virus’ surface.
In addition, plant-produced palivizumab was found to show 50% plaque reduction compared to palivizumab manufactured in recombinant mammalian cells.